title: One size does not fit all: Challenging some dogmas and taboos in drug discovery.
abstract: Advances in genetics, biology, chemical synthesis and computational methods have contributed to the understanding of diseases and drugs and with all of the above, there is an expectation that we are in a better position than ever before to create effective medicines for our needs. The reality is, however, disconnected from the expectation - US FDA drug approval statistics show that the number of approved drugs, especially the first-in-class drugs, is not commensurate with our improved knowledge. In this perspective, we offer our views on the possible reasons for this, focusing on small-molecule drugs and suggest some ideas for further considerations.
authors.affiliation: Department of Pharmacy, 18 Science Drive 4, Faculty of Science, National University of Singapore, Singapore 117543, Singapore.
authors.forename: Christina Ll
authors.initials: CL
authors.lastname: Chai
authors.affiliation: Department of Organic Chemistry, Semmelweis University, Hőgyes E.u.7, H-1092, 1085 Budapest, Hungary.
authors.forename: Péter
authors.initials: P
authors.lastname: Mátyus
mesh_terms: D000818:Animals; D017277:Drug Approval; D055808:Drug Discovery; D057166:High-Throughput Screening Assays; D006801:Humans; D064798:Polypharmacology; D054852:Small Molecule Libraries / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D054852:Small Molecule Libraries
keywords: high-throughput screening; pan assay interference compounds (PAINS); polypharmacology; target-based screening; toxicophores